Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levofloxacin inhalation - Horizon Therapeutics plc

Next Previous
Drug Profile

Levofloxacin inhalation - Horizon Therapeutics plc

Alternative Names: Aeroquin; Inhaled levofloxacin hemihydrate - Horizon Therapeutics plc; MP 376; Quinsair

Latest Information Update: 06 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mpex Pharmaceuticals
  • Developer Adare Pharmaceuticals; Horizon Therapeutics plc
  • Class Anti-infectives; Antibacterials; Fluoroquinolones; Small molecules; Urinary anti-infective agents
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Nontuberculous mycobacterium infections; Respiratory tract infections

Most Recent Events

  • 28 Dec 2022 Discontinued - Preclinical for Bronchiectasis (Non-cystic fibrosis-related) in USA (Inhalation)
  • 28 Dec 2022 Discontinued - Preclinical for Nontuberculous mycobacterium infections in USA (Inhalation)
  • 05 Sep 2021 Interim pharmacodynamics data from a preclinical trial in cystic fibrosis presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top